Zacks Research Has Pessimistic View of CORT Q2 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report released on Monday, May 26th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.23 per share for the quarter, down from their prior estimate of $0.37. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.35 EPS, Q4 2025 earnings at $0.58 EPS, FY2025 earnings at $1.33 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.50 EPS, Q4 2026 earnings at $0.51 EPS, FY2026 earnings at $1.65 EPS, Q1 2027 earnings at $0.66 EPS and FY2027 earnings at $3.81 EPS.

CORT has been the subject of a number of other reports. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 14th. Piper Sandler boosted their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a report on Thursday, April 3rd. Truist Financial set a $135.00 price target on Corcept Therapeutics in a report on Tuesday, May 6th. HC Wainwright cut their price target on Corcept Therapeutics from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $138.25.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $77.65 on Thursday. Corcept Therapeutics has a fifty-two week low of $28.04 and a fifty-two week high of $117.33. The stock has a market cap of $8.23 billion, a price-to-earnings ratio of 61.63 and a beta of 0.22. The business has a fifty day moving average of $71.77 and a 200-day moving average of $63.02. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.17. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $157.21 million during the quarter, compared to analysts’ expectations of $177.93 million. During the same period in the previous year, the firm posted $0.25 earnings per share. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CORT. Synergy Asset Management LLC increased its position in Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after purchasing an additional 262,503 shares in the last quarter. Van ECK Associates Corp purchased a new stake in Corcept Therapeutics during the fourth quarter worth approximately $4,483,000. HighTower Advisors LLC increased its position in shares of Corcept Therapeutics by 30.7% in the fourth quarter. HighTower Advisors LLC now owns 93,677 shares of the biotechnology company’s stock worth $4,720,000 after acquiring an additional 22,011 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of Corcept Therapeutics by 3.0% in the fourth quarter. New York State Teachers Retirement System now owns 128,232 shares of the biotechnology company’s stock worth $6,462,000 after acquiring an additional 3,789 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Corcept Therapeutics by 2.7% in the 4th quarter. JPMorgan Chase & Co. now owns 259,902 shares of the biotechnology company’s stock valued at $13,096,000 after acquiring an additional 6,832 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Corcept Therapeutics

In related news, insider Sean Maduck sold 100,000 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total value of $10,054,000.00. Following the completion of the transaction, the insider now directly owns 85,622 shares in the company, valued at approximately $8,608,435.88. This represents a 53.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 421 shares of the company’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $60.58, for a total value of $25,504.18. Following the completion of the transaction, the insider now owns 9,009 shares of the company’s stock, valued at $545,765.22. The trade was a 4.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 296,352 shares of company stock worth $24,908,205. 20.50% of the stock is currently owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.